All In Biotech

NDA 210365 · Jazz Pharms Res

Epidiolex

Cannabidiol · Oral

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Jun 25, 2018

Approved uses

4

Original approval plus efficacy supplements

Registered trials

462

100 Phase 3, 83 recruiting

FAERS reports

24,103

14,267 serious, 1,929 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 29, 2026.

EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older ( 1 )

Mechanism: The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 20, 2023 Supplement 20 · Efficacy OrphanLetterLabel
  • Jul 31, 2020 Supplement 5 · Efficacy · priority review OrphanLabelLetterReview
  • Jul 31, 2020 Supplement 6 · Efficacy · priority review OrphanLabelLetterReview
  • Jun 25, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • EPIDIOLEX · CANNABIDIOL 100MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cannabidiol" as an intervention, any sponsor and status, largest first.

All 462 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure6,169
  • hospitalisation2,670
  • off label use2,520
  • product use in unapproved indication1,809
  • diarrhoea1,776
  • drug ineffective1,445
  • death1,374
  • somnolence1,340
  • fatigue1,231
  • product dose omission issue1,191
  • weight decreased890
  • weight increased845

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20143
201528
201635
201792
2018232
20193,463
20203,556
20214,386
20223,787
20232,469
20242,045
20252,201
20261,805

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Epidiolex (Cannabidiol (Cbd))

2024 spending

$207M

Beneficiaries

4,517

43,893 claims

Per beneficiary

$45,925

$16.09 per unit

View as table
YearSpending
2020$106,979,035
2021$140,129,330
2022$173,788,785
2023$197,357,912
2024$207,443,287

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 713 on PubMed

Sponsor: Jazz Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.